ABCC7 p.Gly628Arg
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 16442101
[PubMed]
Frelet A et al: "Insight in eukaryotic ABC transporter function by mutation analysis."
No.
Sentence
Comment
295
I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R and L633P resulted in aberrant processing.
X
ABCC7 p.Gly628Arg 16442101:295:49
status: NEW
No.
Sentence
Comment
42
The following mutations have been studied: exon 3: W57G, R74W, R75Q, G85E, 394delTT, 405+ 1G>A; exon 4: E92X, P99L, 441delA, 444delA, 457TAT>G, D110H, R117C, R117H, A120T, 541delC, 544delCA, Q151X, 621+1G>T, 662- 2A>C; exon 7: 1078delT, F331L, R334W, I336K, R347C, R347P, A349V, R352Q, 1221delCT; exon 10: S492F, Q493X, 1609delCA, deltaI507, deltaF508; exon 11: G542X, S549N, G551D, R553X, A559T, R560K, R560T; exon 13: K716X, Q685X, G628R, L719X; exon 17b: H1054D, G1061R, 3320ins5, R1066H, R1066L, R1070Q, 3359delCT, L1077P, H1085R, Y1092X; exon 19: R1162X, 3659delC, 3662delA, 3667del4, 3737delA, I1234V, S1235R, 3849G>A; exon 20: 3860ins31,S1255X,3898insC,3905insT,D1270N, W1282X, Q1291R; and exon 21: N1303H, N1303K, W1316X.
X
ABCC7 p.Gly628Arg 11933191:42:434
status: NEW129 Of those exon 13 mutations that were not detected at 60°C, G628R and Q685X (see Fig. 4) each lies within a domain with a melting temperature of 56°C.
X
ABCC7 p.Gly628Arg 11933191:129:64
status: NEW130 It is therefore understandable that G628R and Q685X did not resolve at 60°C.
X
ABCC7 p.Gly628Arg 11933191:130:36
status: NEW
PMID: 20435887
[PubMed]
Billet A et al: "C terminus of nucleotide binding domain 1 contains critical features for cystic fibrosis transmembrane conductance regulator trafficking and activation."
No.
Sentence
Comment
2
We mutated CFTR amino acids located in the betac5-betac6 hairpin, within the betac5 strand (H620Q), within the beta-turn linking the two beta strands (E621G, G622D), as well as within (S623A, S624A) and at the extremity (G628R) of the betac6 strand.
X
ABCC7 p.Gly628Arg 20435887:2:221
status: NEW3 Functional analysis reveals that the current density was largely reduced for G622D and G628R channels compared with wt CFTR, similar for E621G and S624A, but increased for H620Q and S623A.
X
ABCC7 p.Gly628Arg 20435887:3:87
status: NEW4 For G622D and G628R, the abnormal activity is likely due to a defective maturation process, as assessed by the augmented activity and mature C-band observed in the presence of the trafficking corrector miglustat.
X
ABCC7 p.Gly628Arg 20435887:4:14
status: NEW5 In addition, in presence of the CFTR activator benzo[c]quinolizinium, the CFTR current density compared with that of wt CFTR was abolished for G622D and G628R channels, but similar for H620Q, S623A, and S624A or slightly increased for E621G.
X
ABCC7 p.Gly628Arg 20435887:5:153
status: NEW6 Finally, G622D and G628R were activated by the CFTR agonists genistein, RP-107, and isobutylmethylxanthine.
X
ABCC7 p.Gly628Arg 20435887:6:19
status: NEW33 We have mutated these two glycine residues in aspartic acid (G622D) and arginine (G628R) and considered other mutants in their neighborhood (H620Q, E621G, S623A, and S624A).
X
ABCC7 p.Gly628Arg 20435887:33:82
status: NEW57 C, focus on the Gly628 position, which was mutated in the three-dimensional model in an arginine residue (G628R), highlighting the steric clashes (orange lines), which would be associated with this mutation.
X
ABCC7 p.Gly628Arg 20435887:57:106
status: NEW87 RESULTS Expression of the NBD1 C-terminal CFTR Mutants-We have introduced EGFP-tagged CFTR proteins into HEK293 cells, wt CFTR and six CFTR mutants, i.e. H620Q, E621G, G622D, S623A, S624A, and G628R.
X
ABCC7 p.Gly628Arg 20435887:87:193
status: NEW91 However, no mature-glycosylated C-band form for G622D and G628R was detected (Fig. 2, lanes 6 and 7).
X
ABCC7 p.Gly628Arg 20435887:91:58
status: NEW102 Effect of the CFTR corrector miglustat on G622D and G628R.
X
ABCC7 p.Gly628Arg 20435887:102:52
status: NEW103 A, upper, Western blot showing wt-CFTR, G622D-, and G628R-CFTR expression with or without pretreatment with miglustat (100 M) and detected with CFTR NBD2 C-terminal antibody.
X
ABCC7 p.Gly628Arg 20435887:103:52
status: NEW110 Third, the current densities for G622D and G628R, although not abolished, are both significantly reduced (p Ͻ 0.001) compared with wt (supplemental Table 2).
X
ABCC7 p.Gly628Arg 20435887:110:43
status: NEW115 Because we observed a pronounced reduction of the current density for the mutants G622D and G628R, we incubated transfected HEK293 and BHK-21 cells with this corrector and analyzed the corresponding CFTR activity.
X
ABCC7 p.Gly628Arg 20435887:115:92
status: NEW117 Similarly in BHK-21 cells the iodide efflux responses stimulated by Fsk and genistein was significantly increased for G622D and G628R after treatment with the corrector (Fig. 4B).
X
ABCC7 p.Gly628Arg 20435887:117:128
status: NEW118 This observation indicates that the diminution of cAMP-induced Cl- current is probably due to the diminution or to the absence of a mature form of G622D and G628R mutants.
X
ABCC7 p.Gly628Arg 20435887:118:157
status: NEW119 In support of this hypothesis, Western blot analysis of cells treated with miglustat shows enhanced mature C-band for G622D and G628R mutants (Fig. 4A).
X
ABCC7 p.Gly628Arg 20435887:119:128
status: NEW133 MPB-91 stimulated the Cl- current for each CFTR mutants studied except the glycine mutants G622D and G628R (Fig. 6 and supplemental Table 3).
X
ABCC7 p.Gly628Arg 20435887:133:101
status: NEW134 For them, comparison of the corresponding IV slope (Fig. 7A) did not reveal significant differences between basal condition (I/V slope of G622D, 0.032 Ϯ 0.001, n ϭ 7; G628R, 0.046 Ϯ 0.002, n ϭ 5) and in presence of 50 M MPB-91 (I/V slope of G622D, 0.037 Ϯ 0.001, n ϭ 7; G628R, 0.053 Ϯ 0.003, n ϭ 5) indicating the absence of a response of the two mutated channels to that agent.
X
ABCC7 p.Gly628Arg 20435887:134:179
status: NEWX
ABCC7 p.Gly628Arg 20435887:134:314
status: NEW136 Results in Fig. 8 show a potentiation of the cAMP-dependent Cl- current by MPB-91 for wt channels but neither for G622D nor G628R FIGURE 5.
X
ABCC7 p.Gly628Arg 20435887:136:124
status: NEW141 We also tested analogues of MPB-91 (12), but again for the mutant G622D or G628R, the Cl-channel function of CFTR was not stimulated by MPB-95 and MPB-97 (Fig. 9A).
X
ABCC7 p.Gly628Arg 20435887:141:75
status: NEW143 Importantly, all of these CFTR activators stimulated the Cl-channel activity of G622D and G628R CFTR, suggesting the relative specificity of the effect observed in the presence of the benzoquinolizinium drugs (Fig. 9B).
X
ABCC7 p.Gly628Arg 20435887:143:90
status: NEW146 Using Western blot analysis, we now observed a strong decrease of the mature-glycosylated form for the two mutants G622D and G628R.
X
ABCC7 p.Gly628Arg 20435887:146:125
status: NEW158 Consistently, the defect in the maturation process induced by the G622D and G628R mutations, which causes the retention of the mutated CFTR protein, can be clearly explained by the key role of these glycine residues at the structure level.
X
ABCC7 p.Gly628Arg 20435887:158:76
status: NEW184 In contrast, for the two mutants G622D and G628R, no activation was recorded in the presence of MPB-91 or other MPB compounds.
X
ABCC7 p.Gly628Arg 20435887:184:43
status: NEW187 However, this is not the case since xanthine (isobutylmethylxanthine), RP-107, or iso- flavonoide (genistein) successfully stimulated the channel activity of G622D and G628R CFTR channels.
X
ABCC7 p.Gly628Arg 20435887:187:168
status: NEW188 Therefore, one could hypothesize that the mechanism of activation of CFTR by MPB was itself affected by the mutations G622D and G628R and that the binding site of MPB might be located, on the folded protein, in the vicinity of the last beta hairpin of CFTR NBD1.
X
ABCC7 p.Gly628Arg 20435887:188:128
status: NEW189 However, the perturbation induced by the G622D and G628R mutations on the overall NBD1 structure might be felt at long range and thus influence potential binding sites, which may be distant at the three-dimensional level.
X
ABCC7 p.Gly628Arg 20435887:189:51
status: NEW196 Iodide efflux of G622D and G628R CFTR-expressing cells in the presence of different MPB compounds or different activators.
X
ABCC7 p.Gly628Arg 20435887:196:27
status: NEW
PMID: 20706124
[PubMed]
Lucarelli M et al: "A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation."
No.
Sentence
Comment
103
In vivo findings and, in some cases, in vitro functional characterizations have been reported for [F508C; S1251N],38 [R347H; D979A],39,40 [R74W; D1270N],41 [G628R; S1235R],42,43 [M470V; S1235R],42 [S912L; G1244V],44 [R117H; (TG)mTn],45-47 [R117C; (TG)mTn],46 [S1235R; (TG)mT5],48 [G576A; R668C],10,49 [V562I; A1006E],49 [R352W; P750L],49 [1198_1203del TGGGCT; 1204GϾA],49 [V754M; CFTRdele3_10,14b_16],50 and [F508del; I1027T].51 These complex alleles have been found in patients with either CF or CFTR-RD, although more often in the former.
X
ABCC7 p.Gly628Arg 20706124:103:157
status: NEW
PMID: 20717170
[PubMed]
Rene C et al: "p.Ser1235Arg should no longer be considered as a cystic fibrosis mutation: results from a large collaborative study."
No.
Sentence
Comment
11
However, a clear statement on the pathogenicity of a mutation is difficult to obtain, in particular for missense mutations.2,3 Moreover, the existence of at least two mutations or sequence variations on the same allele, named complex alleles, complicates genetic counseling.4-11 p.Ser1235Arg (3837T4G or c.3705T4G), initially reported by Cuppens et al.12 with a second mutation on the same allele, p.Gly628Arg, is located in a poorly conserved region in the second nucleotide binding fold (NBF2).
X
ABCC7 p.Gly628Arg 20717170:11:400
status: NEW134 These data are consistent with previous functional study of this locus in combination with alleles found at p.Met470Val and p.Gly628Arg loci.13 Wei et al.13 demonstrated that the p.Ser1235Arg CFTR protein does not cause change in the chloride transport activity.
X
ABCC7 p.Gly628Arg 20717170:134:126
status: NEW135 Besides, the p.Gly628Arg/p.Ser1235Arg mutant protein induces a significantly lower cAMP-dependent chloride transport activity than the Figure 1 Structural and processing impact of p.Ser1235Arg mutation on the CFTR protein.
X
ABCC7 p.Gly628Arg 20717170:135:15
status: NEW144 p.Gly628Arg mutant protein, showing the major importance of genetic background, particularly for missense mutations.
X
ABCC7 p.Gly628Arg 20717170:144:2
status: NEW
PMID: 9736778
[PubMed]
Vankeerberghen A et al: "Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
1
Nine of these (I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R and L633P) resulted in aberrant processing.
X
ABCC7 p.Gly628Arg 9736778:1:64
status: NEW66 The mutations that gave rise to a protein that was not able to proceed to the 190 kDa form (I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R and L633P; Table 2) are therefore class two mutations (17), where the disease phenotype is caused by the absence of sufficient CFTR protein at the cell surface.
X
ABCC7 p.Gly628Arg 9736778:66:141
status: NEW68 Primers used for mutagenesis Primer Sequence I601F (a1933t) 5'-CTA ACA AAA CTA GGT TTT TGG TCA CTT C-3' L610S (t1961c) 5'-CTA AAA TGG AAC ATT CAA AGA AAG CTG-3' A613T (g1969a) 5'-CAT TTA AAG AAA ACT GAC AAA ATA TTA-3' D614G (a1973g) 5'-CAT TTA AAG AAA GCT GGC AAA ATA TTA A-3' I618T (t1985c) 5'-GAC AAA ATA TTA ACT TTG CAT GAA GG-3' L619S (t1988c) 5'-GAC AAA ATA TTA ATT TCG CAT GAA GGT-3' H620P (a1991c) 5'-CAA AAT ATT AAT TTT GCC TGA AGG TAG C-3' H620Q (t1992g) 5'-AAT ATT AAT TTT GCA GGA AGG TAG CAG-3' G622D (g1997a) 5'-TTG CAT GAA GAT AGC AGC TAT TTT TAT G-3' G628R (g2014c) 5'-GCA GCT ATT TTT ATC GGA CAT TTT C-3' L633P (t2030c) 5'-CAT TTT CAG AAC CCC AAA ATC TAC AGC-3' D648V (a2075t) 5'-CTC ATG GGA TGT GTT TCT TTC GAC C-3' T665S (a2125t) 5'-CAA TCC TAA CTG AGT CCT TAC ACC G-3' F693L (t2209c) 5'-CAG ACT GGA GAG CTT GGG GAA AAA AG-3' R766M (g2429t) 5'-GCA CGA AGG ATG CAG TCT GTC CTG-3' R792G (c2506g) 5'-CAG CAT CCA CAG GAA AAG TGT CAC TG-3' A800G (c2531g) 5'-CTG GCC CCT CAG GGA AAC TTG ACT G-3' I807M (a2553g) 5'-CTG AAC TGG ATA TGT ATT CAA GAA GG-3' E822K (g2596a) 5'-GGC TTG GAA ATA AGT AAA GAA ATT AAC G-3' E826K (g2608a) 5'-GAA GAA ATT AAC AAA GAA GAC TTA AAG-3' Selection primer BstBI 5'-CTC TGG GGT CCG GAA TGA CCG AC-3' Two primers were used for each mutagenesis reaction.
X
ABCC7 p.Gly628Arg 9736778:68:565
status: NEW77 Mutations detected in patients (I601F, L610S, A613T, D614G, I618T, L619S, H620P, H620Q, D622G, G628R, L633P, T665S, F693L, K698R, V754M, R766M, R792G, A800G, I807M, E822K and E826K) are indicated in bold and underlined, the PKA phosphorylation sites by an arrow and the two acidic domains are boxed.
X
ABCC7 p.Gly628Arg 9736778:77:95
status: NEW87 Maturation pattern of RD mutations and their associated phenotype found in patients with the indicated genotype (when the mutation is associated with CF, only the pancreas status is given) Mutation A-form B-form C-form Clinical data Genotype Phenotype Reference I601F + + - I601F/G542X PS M. Schwarz, personal communication L610S + + - Unknown Unknown A613T + + - Unknown Unknown D614G + + - D614G/unknown PI 14 I618T + + - I618T/dF508 PS G.R. Cutting, personal communication L619S + + - L619S/unknown PI B. Tümmler, personal communication H620P + + - H620P/R1158X PS M. Schwarz, personal communication H620Q + + + H620Q/dF508 PI T. Dörk, personal communication G622D + + + G622D/unknown Oligospermia J. Zielenski, personal communication G628R + + - Unknown Unknown L633P + + - L633P/3659delC M. Schwarz, personal communication D648V + + + D648V/3849+10kb C/T PI C. Ferec, personal communication T665S + + + Unknown Unknown F693L + + + F693L/W1282X Healthy C. Ferec; CF Genetic Analysis Consortium R766M + + + R766M/R792G CBAVD D. Glavac, personal communication R792G + + + R766M/R792G CBAVD D. Glavac, personal communication A800G + + + A800G/unknown CBAVD 34 I807M + + + I807M/unknown CBAVD Our observation E822K + + + E822K/unknown PI 35 E826K + + + E826K/unknown Thoracic sarcoidosis C. Bombieri, personal communication +, the protein matures up to that form; -, the protein does not reach the respective maturation step.
X
ABCC7 p.Gly628Arg 9736778:87:748
status: NEW109 Nine mutations caused aberrant processing: I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R and L633P.
X
ABCC7 p.Gly628Arg 9736778:109:92
status: NEW
PMID: 22722932
[PubMed]
Hudson RP et al: "Conformational changes relevant to channel activity and folding within the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
308
Mutations of residues in these C-terminal strands of NBD1, specifically G622D and G628R, have been demonstrated to perturb the pharmacological effects of dual "MPB (benzo(c)- quinolizinium)" compounds, characterized by their ability to both activate CFTR and rescue defective trafficking (56).
X
ABCC7 p.Gly628Arg 22722932:308:82
status: NEW306 Mutations of residues in these C-terminal strands of NBD1, specifically G622D and G628R, have been demonstrated to perturb the pharmacological effects of dual "MPB (benzo(c)- quinolizinium)" compounds, characterized by their ability to both activate CFTR and rescue defective trafficking (56).
X
ABCC7 p.Gly628Arg 22722932:306:82
status: NEW
PMID: 12127423
[PubMed]
Girodon E et al: "Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis."
No.
Sentence
Comment
99
S1235R was first reported in a severely affected CF patient, who also carried the G628R mutation on the same allele [40].
X
ABCC7 p.Gly628Arg 12127423:99:82
status: NEW100 S1235R was subsequently detected without G628R in CF patients [32], in patients with CBAVD [12,49], and even in female healthy CF carriers (Claustres, Fe´rec, personal communications), but not in fertile male CF carriers.
X
ABCC7 p.Gly628Arg 12127423:100:41
status: NEW
PMID: 10923036
[PubMed]
Claustres M et al: "Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France."
No.
Sentence
Comment
109
h M1K, K14X, W19X, 211delG, G27E, R31C, 237insA, 241delAT, Q39X, 244delTA, 296+2T>C, 297-3C>T, W57X+F87L, 306delTAGA, P67L, A72D, 347delC, R75Q, 359insT, 394delT, 405+4A>G, Q98R, 457TAT>G, R117H+5T, R117H+I1027T, R117L, R117P, H139R, A141D, M152V, N186K, D192N, D192del, E193X, 711+1G>A, 711+3A>G, 712-1G>T, L206F, W216X, C225R, Q237E, G241R, 852del22, 876-14del12, 905delG, 993del5, E292K, Y304X, F311del, 1161delC, R347L, R352Q, W361R, 1215delG, S364P, S434X, D443Y, S466X, C491R, T501A, I506T, F508C, I507del+F508C, F508del+L467F, 1774delCT, R553G, 1802delC, 1806delA, A559E, Y563N, 1833delT, Y569C, Y569H, Y569X, G576X, G576A, T582I, 1898+3A>G+186-13C>G, 1918delGC, R600G, L610S, G628R, 2043delG, 2118del4, E664X, 2174insA, Q689X, K698R, K716X, L732X, 2347delG, 2372del8, R764X, 2423delG, S776X, 2634insT, 2640delT, C866Y, 2752-1G>T, W882X, Y913C, V920M, 2896insAG, H939D, H939R, D979V, D985H, D993Y, 3120G>A, I1005R, 3195del6, 3293delA, 3320ins5, W1063X, A1067T, 3359delCT, T1086I, W1089X, Y1092X+S1235R, W1098X, E1104X, R1128X, 3532AC>GTA, 3548TCAT>G, M1140del, 3600G>A, R1162L, 3667ins4, 3732delA+K1200E, S1206X, 3791delC, S1235R+5T, Q1238R, Q1238X, 3849+4A>G, T1246I, 3869insG, S1255P, R1283K, F1286S, 4005+1G>T, 4006-8T>A, 4015delA, N1303H, N1303I, 4172delGC, 4218insT, 4326delTC, Q1382X, 4375-1C>T, 4382delA, D1445N, CF40kbdel4-10, Cfdel17b.
X
ABCC7 p.Gly628Arg 10923036:109:684
status: NEW
PMID: 9175873
[PubMed]
Annereau JP et al: "A novel model for the first nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
70
The maturation patterns of six mutant R domain proteins were determined (Fig. 3): CFTR-L610S, CFTR-G628R and CFTR-L633P matured to the core-glycosylated form, while CFTR-D648V, CFTR-T665S and CFTR-R766M matured to the complete glycosylated form.
X
ABCC7 p.Gly628Arg 9175873:70:99
status: NEW150 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Gly628Arg 9175873:150:34
status: NEW151 The mutations L610S (tc at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleotide and amino acid assignment according to [2]) were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech, Heidelberg, Germany).
X
ABCC7 p.Gly628Arg 9175873:151:34
status: NEW
PMID: 8844211
[PubMed]
Duarte A et al: "Complex cystic fibrosis allele R334W-R1158X results in reduced levels of correctly processed mRNA in a pancreatic sufficient patient."
No.
Sentence
Comment
38
Other in cis missense mutations have been reported, namely F508C-Sl251N (Kalin et al., 1992), G628R- S1235R (Mercier et al., 1995) and R74W- D1270N (Verlingue et al., 1993).
X
ABCC7 p.Gly628Arg 8844211:38:94
status: NEW
PMID: 7529962
[PubMed]
Mercier B et al: "Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients."
No.
Sentence
Comment
65
In addition, we identified the following missense mutations: four R668C, one A800G, one (G628R + S1235R, borne on the same chromosome), one (R74W + D1270N, borne on the same chromosome), six R117H, one F1052V, one R117C, one S1235R, one G149R, one R258G, two R347H, one R1066H, one R75L, and one E193K.
X
ABCC7 p.Gly628Arg 7529962:65:89
status: NEW77 of Patients Genotypea 1 AF508 + (G628R + S1235R) 1 AF508 + (R74W + D1270N) 2 AF508 + R668C 4 AF508 + R117H 1 AF508 + R258G 1 AF508 + R75L 1 E193K + N1303K 1 R347H + R1066H 1 R117C + W1282X 1 R553X + R668C 1 G149R + R668C 1 R117H+R117H 18 AF508/unidentified 4 W1282X/unidentified 1 G542X/unidentified 1 N1303K/unidentified 1 S1235R/unidentified 1 R347H/unidentified 1 A800G/unidentified 1 F1052V/unidentified 23 unidentified/unidentified a In parentheses are the two mutations located on the same haplotype.
X
ABCC7 p.Gly628Arg 7529962:77:33
status: NEW85 It has been reported elsewhere that such an amino acid change could be considered as mild, as for G628R in exon 13 (Fanen et al. 1992) and G1061R in exon 17b (Mercier et al.
X
ABCC7 p.Gly628Arg 7529962:85:98
status: NEW
No.
Sentence
Comment
593
Not surprisingly, Rl17H is associated with CF only when the allele also contains Table 2 Examples of complex alleles in the CfTR gene Principal Second site mutationa Location alteration Location Reference R75X exon 3 125G --.. C promoter 57 405 + IG --.. A intron 3 3030G --.. A exon 15 57 R1l7H exon 4 129G --.. C promoter 203 RI17H exon 4 IVS8 : 5T or 7T intron 8 101 R297Q exon 7 IVS8 : 5T or 7T intron 8 60 aF508 exon 10 R553Q exon II 59 aF508 exon 10 1I027T exon I7a 57 8F508 exon 10 deletion of D7S8 500 kb 3' of 186 CfTR S549N exon II R75Q exon 3 205a L619S exon 13 1716G � A exon 10 57 G628R (G � C) exon 13 SI235R exon 19 47 2184insA exon 13 IVS:5T exon 9 J Zielenski, J Bal, 0 Markiewicz, L-C Tsui, unpublished data A800G exon 13 IVS8 : 5T or 7T intran 8 31 S912L exon 15 GI244V exon 20 149 GlO69R exon 17b L88X exon 3 149 3732deiA exon 19 Kl200E exon 19 70 3849 + IOkbC � intron 19 R668C exon 13 57 T SI251N exon 20 F508C exon 10 94 The status of principal mutation may not be clear in every case; e.g. G628R(G --> C) vs S1235R.
X
ABCC7 p.Gly628Arg 8825494:593:603
status: NEW
PMID: 7526685
[PubMed]
Morral N et al: "Independent origins of cystic fibrosis mutations R334W, R347P, R1162X, and 3849 + 10kbC-->T provide evidence of mutation recurrence in the CFTR gene."
No.
Sentence
Comment
112
CT................... 3863: G--oA .................. G-.T ................... 3980: G-jA .................. G--)T.................... 4374+1: G-A .................. G--oT.................... L88S L88X L88X G. Malone, personal communication Savov et al. 1994b Macek et al. 1992 406-1G--.C Bonizzato et al. 1992 406-1G- T T. Bienvenu, personal communication E92K Nunes et al. 1993 E92X Will et al. 1994 S549N Cutting et al. 1990 S5491 Kerem et al. 1990 R560K Ferec et al. 1992 R560T Kerem et al. 1990 Y563D A. Hamosh, personal communication Y563N Kerem et al. 1990 1898+1CG-.A Strong et al. 1992 1898+1GC-.C Cuppens et al. 1993 1898+3A-)C W. Lissens, personal communication 1898+3A--4G Cremonesi et al. 1992 G628R G628R 2183AA- G 2184delA 2184insA M1101K M1101R 3667del4 3667ins4 3791delC T12201 G1244E G1244V R1283K R1283M Fanen et al. 1992 Cuppens et al. 1993 Bozon et al. 1994 Dork et al., in press N. Kilin, personal communication Zielenski et al. 1993 Mercier et al. 1993 Chillon et al. 1994a Sangiuolo et al. 1993 M. Macek, Jr., personal communication Ghanem et al. 1994 Devoto et al. 1991 Savov et al. 1994a Chevalier et al., in press Cheadle et al. 1992 4374+1G-*A Fanen et al. 1992 4374+1G--iT Dork et al. 1993 of the most common allele.
X
ABCC7 p.Gly628Arg 7526685:112:705
status: NEW
PMID: 7508414
[PubMed]
Cuppens H et al: "Detection of 98.5% of the mutations in 200 Belgian cystic fibrosis alleles by reverse dot-blot and sequencing of the complete coding region and exon/intron junctions of the CFTR gene."
No.
Sentence
Comment
74
Another G628R CF allele, caused by another nucleotide substitution involving the same nucleotide mutated in G628R(G-~C), has also been observed (10), indicating that this mutation is associated with a defective CFTR protein.
X
ABCC7 p.Gly628Arg 7508414:74:8
status: NEW73 Another G628R CF allele, caused by another nucleotide substitution involving the same nucleotide mutated in G628R(G-~C), has also been observed (10), indicating that this mutation is associated with a defective CFTR protein.
X
ABCC7 p.Gly628Arg 7508414:73:8
status: NEW
PMID: 1379210
[PubMed]
Fanen P et al: "Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions."
No.
Sentence
Comment
64
One was in a patient heterozygous for a G-to-A transition at nucleotide position 2014 (G628R in the numbering system of Riordan) (Riordan et al., 1989).
X
ABCC7 p.Gly628Arg 1379210:64:87
status: NEW67 T C225R R334W G542X G551D 1717-l G -+ A K710X Lys -b Stop at 710 A-+Tat2260 G628R Gly + Arg at 628 G+Aat2014 2043 delG Frameshift 1 -bp deletion W846X Trp --, Stop at 846 G-+Aat2670 2789 + 5 G - A Splice mutation G + A at 2789 + 5 Y913C Tyr --) Cys at 913 A-,Gat2870 3272-26 A -+ G Splice mutation A + G at 3272-26 W1063X Trp -+ Stop at 1063 G+Aat3321 R1066C Arg + Cys at 1066 C+Tat3328 Y1092X Tyr + Stop at 1092 C + A at 3408 3659delC Frameshift l-bp deletion 19 3732deIA Frameshift 1-bp deletion 19 K1200E Lys --, Glu at 1200 A+Gat3730 19 R1162X Arg - Stop at 1162 C + T at 3616 19 W1282X Trp + Stop at 1282 G+Aat3978 20 N1303K Asn -+ Lys at 1303 C -+ G at 4041 21 4374 + 1 G + A Splice mutation G+Aat4374+ 1 Intron 23 Asp + Gly at 44 Frameshift Frameshift Gly + Arg at 178 Splice mutation Cys + Arg at 225 Arg + Trp at 334 Gly + Stop at 542 Gly + Asp at 551 Splice mutation A+Gat263 2 2bp deletion 2 1-bp deletion 4 G --, A at 664 5 G + Tat 711 + 1 Intron 5 T+Cat805 6a C + Tat 1132 7 G + T at 1756 11 G+Aat1784 11 G + A at 1717-l Intron 10 Haplotype Restriction (XV-2c, KM-19) site change Reference A B A A or C A D A B, D B B Hinfl(-) - - - - SecI (+) MspI (6) - Mb01 (+) - 13 13 13 14a Intron 14 b 15 Intron 17a 17b 17b 17b C A B A D A A C B C XmnI (-) - - - MnlI (-) - - This study This study This study Zielenski et al. (1991) Zielenski et al. (1991) This study Gasparini et al. (1991b) Kerem et al. (1990) Cutting et al. (1990) Kerem et al. (1990); Guillermit et al. (1990) This study This study This study Vidaud et al. (1990a) Highsmith et al. (1990) Vidaud et al. (1990a) This study This study This study Bozon (personal communication) Kerem et al. (1990) This study Together with 3732delA Gasparini et al. (1991b) Vidaud et al. (1990a) Osborne et al. (1991) This study Note. Previously undescribed mutations are shown in bold type.
X
ABCC7 p.Gly628Arg 1379210:67:76
status: NEW
PMID: 10812063
[PubMed]
Wei L et al: "Suppressive interactions between mutations located in the two nucleotide binding domains of CFTR."
No.
Sentence
Comment
0
Suppressive interactions between mutations located in the two nucleotide binding domains of CFTR Lin Weia , Anne Vankeerberghenb , Martine Jaspersb , Jean-Jacques Cassimanb , Bernd Niliusa , Harry Cuppensb; * a Department of Physiology, University of Leuven, B-3000 Leuven, Belgium b Center for Human Genetics, University of Leuven, Gasthuisberg OpN6, Herestraat 49, B-3000 Leuven, Belgium Received 24 March 2000 Edited by Maurice Montal Abstract The S1235R locus in CFTR was studied in combination with alleles found at the M470V and G628R loci.
X
ABCC7 p.Gly628Arg 10812063:0:535
status: NEW2 The impact of R1235 was found to be influenced by the alleles present at the G628R and M470V loci.
X
ABCC7 p.Gly628Arg 10812063:2:77
status: NEW15 The S1235R amino acid alteration is such a mutation. It was 'rst found in a cystic 'brosis (CF) patient who carried S1235R and G628R (gCc) on the same allele [9].
X
ABCC7 p.Gly628Arg 10812063:15:127
status: NEW29 The di&#a1;erent amino acid alterations, V470M, G628R and S1235R, were introduced using the Transformer Site-Directed Mutagenesis kit (Clontech Laboratories, Inc., Palo Alto, CA, USA).
X
ABCC7 p.Gly628Arg 10812063:29:48
status: NEW86 Two R1235 CFTR genes were found on the normal CFTR alleles of CF mothers, one was found in a CF patient who carried a second missense mutation G628R (gCc) on the same allele [9], one was from a patient with borderline sweat chloride values who was compound heterozygote for R1235 and vF508, and two R1235 CFTR genes were found in random individuals.
X
ABCC7 p.Gly628Arg 10812063:86:143
status: NEW117 An interaction between both nucleotide binding domains might be supported by the whole cell data obtained for the alleles at the G628R locus.
X
ABCC7 p.Gly628Arg 10812063:117:129
status: NEW
PMID: 11001817
[PubMed]
Chen JM et al: "Definition of a "functional R domain" of the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
30
Second, while I601F, L610S, A613T, D614G, I618T, L619S, H620P, G628R, and L633P resulted in aberrant processing, neither D648V or T665S caused an arrest in protein maturation (8).
X
ABCC7 p.Gly628Arg 11001817:30:63
status: NEW
PMID: 25443471
[PubMed]
Marion H et al: "The p.Gly622Asp (G622D) mutation, frequently found in Reunion Island and in black populations, is associated with a wide spectrum of CF and CFTR-RD phenotypes."
No.
Sentence
Comment
12
Two nucleotide substitutions were reported in the CFTR gene (NM_000492.3) at position 628 giving rise to p.Gly628Arg (G628R) in CF patients, c.1882G N A and c.1882G N C, while one mutation has been described at position 622, c.1865G N A, p.Gly622Asp (G622D), reported in 1998 by Zielenski et al. in a patient with oligospermia (http:// www.genet.sickkids.on.ca/cftr/) [1].
X
ABCC7 p.Gly628Arg 25443471:12:107
status: NEWX
ABCC7 p.Gly628Arg 25443471:12:118
status: NEW